GlassScriptPhysician profile
Jay D Holland
NPI 1235163353
$3,199.02
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $905 · 2021: $980 · 2022: $370 · 2023: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $548.31 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $369.43 | 2019-2023 | Xifaxan, Trulance |
| Abbott Laboratories | $279.81 | 2021-2023 | Freestyle Libre 3 |
| Abbvie INC. | $229.33 | 2020-2023 | |
| Upsher-Smith Laboratories LLC | $182.06 | 2020-2023 | |
| Glaxosmithkline, LLC. | $168.27 | 2020-2023 | Shingrix |
| Pfizer INC. | $143.09 | 2019-2023 | |
| Esperion Therapeutics, INC. | $134.44 | 2021 | |
| Lilly USA, LLC | $125.99 | 2019-2020 | |
| Amgen INC. | $125.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $116.66 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $71.27 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.99 | 2019-2021 | |
| Genentech USA, INC. | $57.87 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $55.45 | 2022-2023 | Quviviq |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.72 | 2019 | |
| Antares Pharma, INC. | $46.56 | 2022 | |
| Paratek Pharmaceuticals, INC. | $45.79 | 2022 | |
| Eisai INC. | $39.91 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $38.14 | 2020-2021 | |
| Boston Scientific Corporation | $38.08 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $25.56 | 2021-2022 | |
| Astellas Pharma US INC | $24.50 | 2023 | Veozah |
| Insulet Corporation | $22.98 | 2021 | |
| Shire North American Group INC | $22.26 | 2019 | |
| Exact Sciences Corporation | $22.23 | 2023 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $21.72 | 2021 | |
| Medicure Pharma INC. | $21.42 | 2021 | |
| Ibsa Pharma INC. | $17.52 | 2022 | |
| Nestle Healthcare Nutrition INC. | $17.36 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.62 | 2020 | |
| Celgene Corporation | $14.24 | 2019 | |
| Medtronic Vascular, INC. | $14.19 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Holland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.